Evaluation of vilazodone for the treatment of depressive and anxiety disorders

References

• World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017.
   Google Scholar
• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679.
   PubMed Web of Science ®Google Scholar
• Bauer M, Pfennig A, Severus E, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental heatlh disorders. 5th ed. Washington DC: American Psychiatric Association; 2013.
   Google Scholar
• Wille SM, Cooreman SG, Neels HM, et al. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008;45(1):25–89.
   PubMed Web of Science ®Google Scholar
• Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164(2):201–204.
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459.
   PubMedGoogle Scholar
• Stahl SM, Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215–235.
   PubMed Web of Science ®Google Scholar
• Za H, Kr S, Cj L, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005;510(1–2):49–57.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug approval package. Viibryd (vilazodone hydrochloride) Tablets. 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf [Last accessed 2018 Nov 5].
   Google Scholar
• Viibryd (vilazodone). prescribing information. St. Louis, MO: Forest Pharmaceuticals, LLC; 2015.
   Google Scholar
• Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI? Expert Opin Drug Discov. 2013;8(12):1529–1539.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014;19(2):105–109.
   PubMed Web of Science ®Google Scholar
• de Paulis T. Drug evaluation: vilazodone-a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007;10(3):193–201.
   PubMed Web of Science ®Google Scholar
• Zt S, Banerjee P, Fi T. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov. 2016;11(5):515–523.
   PubMed Web of Science ®Google Scholar
• Ashby CR, Kehne JH, Bartoszyk GD, et al. Electrophysiological evidence for rapid 5-HT(1)A autoreceptor inhibition by vilazodone, a 5-HT(1)A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol. 2013;714(1–3):359–365.
   PubMed Web of Science ®Google Scholar
• Baselt RC. Disposition of toxic drugs and chemicals in man. 11th edition. Seal Beach, CA: Biomedical Publications; 2017.
   Google Scholar
• Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326–333.
   PubMed Web of Science ®Google Scholar
• Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(4):441–447.
   PubMed Web of Science ®Google Scholar
• Croft HA, Pomara N, Gommoll C, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):E1291–E1298.
   PubMed Web of Science ®Google Scholar
• Mathews M, Gommoll C, Chen D, et al. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(2):67–74.
   PubMed Web of Science ®Google Scholar
• Rele S, Millet R, Kim S, et al. An 8-week randomized, double-blind trial comparing efficacy, safety, and tolerability of 3 vilazodone dose-initiation strategies following switch from SSRIs and SNRIs in major depressive disorder. Prim Care Companion CNS Disord. 2015;17:4.
   Google Scholar
• Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31(5):643–646.
   PubMed Web of Science ®Google Scholar
• Durgam S, Chen C, Migliore R, et al. A phase 3, double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder. Pediatr Drugs. 2018;20:353–363.
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Driscoll D, Reist C, et al. A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression. Prim Care Companion CNS Disord. 2017;19:4.
   Google Scholar
• Grant JE, Redden SA, Leppink EW. Double-blind switch study of vilazodone in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2017;32(3):121–126.
   PubMed Web of Science ®Google Scholar
• Eyre H, Siddarth P, Cyr N, et al. Comparing the immune-genomic effects of vilazodone and paroxetine in late-life depression: a pilot study. Pharmacopsychiatry. 2017;50(6):256–263.
   PubMed Web of Science ®Google Scholar
• Bathla M, Anjum S, Singh M, et al. A 12-week comparative prospective open-label randomized controlled study in depression patients treated with vilazodone and escitalopram in a tertiary care hospital in North India. Indian J Psychol Med. 2018;40(1):80–85.
   PubMedGoogle Scholar
• Durgam S, Gommoll C, Migliore R, et al. Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018;33(6):304–311.
   PubMed Web of Science ®Google Scholar
• Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US food and drug administration’s approval of a new antidepressant. J Clin Psychiatry. 2011;72(9):1166–1173.
   PubMed Web of Science ®Google Scholar
• Kirsch I. Antidepressants and the placebo effect. Z Psychol. 2014;222(3):128–134.
   PubMed Web of Science ®Google Scholar
• Kornstein S, Chang CT, Gommoll CP, et al. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2018;33(4):217–223.
   PubMed Web of Science ®Google Scholar
• He H, Wang W, Lyu J, et al. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: a PRISMA-compliant meta-analysis. J Psychiatr Res. 2018;96:247–259.
   PubMed Web of Science ®Google Scholar
• Khan A, Durgam S, Tang X, et al. Post hoc analyses of anxiety measures in adult patients with generalized anxiety disorder treated with vilazodone. Prim Care Companion CNS Disord. 2016;18:2.
   Google Scholar
• Thase ME, Chen D, Edwards J, et al. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(6):351–356.
   PubMed Web of Science ®Google Scholar
• Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:Cd006115.
   Google Scholar
• Gommoll C, Durgam S, Mathews M, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety. 2015;32(6):451–459.
   PubMed Web of Science ®Google Scholar
• Gommoll C, Forero G, Mathews M, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol. 2015;30(6):297–306.
   PubMed Web of Science ®Google Scholar
• Durgam S, Gommoll C, Forero G, et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial. J Clin Psychiatry. 2016;77(12):1687–1694.
   PubMed Web of Science ®Google Scholar
• Schneier FR, Moskow DM, Choo TH, et al. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. Depress Anxiety. 2017;34:1085–1095.
   PubMed Web of Science ®Google Scholar
• Careri JM, Draine AE, Hanover R, et al. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord. 2015;17:6.
   Google Scholar
• Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. Asian J Psychiatr. 2017;26:115–122.
   PubMed Web of Science ®Google Scholar
• Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012;66(4):356–368.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kennedy SH, Edwards JB, et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med. 2013;10(10):2465–2476.
   PubMed Web of Science ®Google Scholar
• Wagner G, Schultes MT, Titscher V, et al. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. J Affect Disord. 2018;228:1–12.
   PubMed Web of Science ®Google Scholar